SCHOTT Pharma KGaA Future Growth
Future criteria checks 3/6
SCHOTT Pharma KGaA is forecast to grow earnings and revenue by 15.7% and 12.2% per annum respectively. EPS is expected to grow by 15.7% per annum. Return on equity is forecast to be 21.1% in 3 years.
Key information
15.7%
Earnings growth rate
15.7%
EPS growth rate
Life Sciences earnings growth | 21.7% |
Revenue growth rate | 12.2% |
Future return on equity | 21.1% |
Analyst coverage | Good |
Last updated | 08 May 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
9/30/2026 | 1,300 | 233 | 81 | 285 | 8 |
9/30/2025 | 1,149 | 189 | 31 | 245 | 9 |
9/30/2024 | 981 | 151 | -16 | 214 | 8 |
12/31/2023 | 906 | 158 | 37 | 220 | N/A |
9/30/2023 | 899 | 152 | 6 | 182 | N/A |
6/30/2023 | 873 | 143 | 70 | 215 | N/A |
9/30/2022 | 821 | 125 | 29 | 182 | N/A |
9/30/2021 | 649 | 101 | 34 | 132 | N/A |
9/30/2020 | 584 | 77 | 19 | 104 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1SXP's forecast earnings growth (15.7% per year) is above the savings rate (0.7%).
Earnings vs Market: 1SXP's earnings (15.7% per year) are forecast to grow slower than the German market (17.2% per year).
High Growth Earnings: 1SXP's earnings are forecast to grow, but not significantly.
Revenue vs Market: 1SXP's revenue (12.2% per year) is forecast to grow faster than the German market (5.3% per year).
High Growth Revenue: 1SXP's revenue (12.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1SXP's Return on Equity is forecast to be high in 3 years time (21.1%)